Academic Bibliography

*First editorial contributions by a pharmacist in the Medical Journal of Australia. 

​

1. Berbatis CG. Adverse reactions to drugs. Part I: Problems of recognition and communication. Aust J Pharm 1972; 53: 503-507. 

 

2. Berbatis CG. Adverse reactions to drugs. Part II: Toxic effects, intolerance and idiosyncrasy. Aust J Pharm 1972; 53: 653-657. 

 

3. Berbatis CG. Adverse reactions to drugs. Part III: Allergic reactions to drugs. Aust J Pharm 1972; 53: 741-745. 

 

4. Berbatis CG. Adverse reactions to drugs. Part IV: Drug-induced disease (pathobiosis). Aust J Pharm 1972; 53: 821-824. 

 

5. Berbatis CG, Eckert GM, Robertson TI. Phase IV evaluation and the hospital pharmacist. Aust J Hosp Pharm 1976; 5: 44-47. 

 

6. Berbatis CG, Rothwell JP. Preventing adverse reactions - identifying the patient at risk. Aust J Hosp Pharm 1976; 6: 4-8. 

 

7. Berbatis CG, Eckert M. Positive aspects of monitoring of drug therapy. Aust J Hosp Pharm 1976; 6: 153-155. 

 

8. Berbatis CG, Eckert GM, Woods V. Nephropathy associated with rifampicin. Aust J Hosp Pharm 1976; 6: 171-173. 

 

9. Berbatis CG, Diekman J, Eckert GM, Frost G. Oxidant type haemolytic anaemia in a glucose-6-phosphate dehydrogenase deficient individual - a problem in patient compliance. Aust J Hosp Pharm 1977; 7: 44-47. 

 

10. Berbatis CG, Eckert GM, Savdie E. Oxidant haemolysis associated with sulphamethizole toxicity. Aust J Pharm 1977; 58: 397-400. 

 

11. Berbatis CG, Eckert GM, Gipps E. Liver damage associated with drug therapy. Aust J Pharm 1977; 58: 269-274. 

 

12. Berbatis CG, Eckert GM, Rothwell JP, Wolfenden WH. Wilson's Disease - problems associated with penicillamine. Aust J Hosp Pharm 1978; 8: 77-79. 

 

13. Berbatis CG, Smith PB. Drug bulletins and local drug utilisation studies. Aust J Hosp Pharm 1978; 8: 47-50. 

 

14. Berbatis CG, Diekman J, Eckert GM, Radvan GH. Biochemical indicators of morbidity and management - lactic acidosis and phenformin. Aust J Hosp Pharm 1978; 8: 60-62. 

 

15. Basger B, Berbatis CG, Eckert GM. Resolving a drug interaction - hypokalaemia in a patient with renal failure. Aust J Hosp Pharm 1978; 8: 68-70. 

 

16. Berbatis CG, Eckert GM, Neale FC, Rothwell JP. Quality assurance of drug therapy - the pharmacist in the review of dosage regimens of patients with raised serum creatinine. Med J Aust 1979; 1: 46-47. 

 

17. Berbatis CG, Eckert GM, Thomas J. The post-registration surveillance of drugs: the role of the pharmacist. Aust J Pharm Sci 1978; 7: 101-109. 

 

18. Berbatis CG, Rohr JB. Guidelines for topical antimicrobials. Aust J Pharm 1978; 59: 671-673. 

 

19. *Editorial (Berbatis CG, Eckert GM). Drug safety in Australia and A.D.E.C. Med J Aust 1979; 1: 433-434. 

 

20. Wojnar-Horton R, Berbatis CG, Brown C, Haslam Y. Drug review in the elderly - review of drug therapy in patients transferred to a convalescent annexe of a major hospital. Aust J Pharm 1979; 60: 239-242. 

 

21. Berbatis CG, Herrmann RP, Kailis SG. Aplastic anaemia associated with phenylbutazone - evaluation of treatment. Aust J Pharm 1979; 60: 797-801. 

 

22. Berbatis CG, Eckert GM. Drug safety in Australia: activities of the Australian Drug Evaluation Committee 1963-79. Aust J Pharm 1979; 60: 873-877. 

 

23. Berbatis CG, Blackbourn J, Hislop IG. Surveillance of a newly registered drug in a hospital. Aust J Hosp Pharm 1979; 9: 91-93. 

 

24. *Editorial (Berbatis CG). Drug and laboratory usage in Australian hospitals. Med J Aust 1980; 1: 148-149. 

 

25. Berbatis CG, Blackbourn J, Smith PB. Drug and laboratory usage in Australian hospitals: pharmacists in assessment and quality assurance. Aust J Pharm 1981; 62: 306-312. 

 

26. McGechie DB, Kenner DJ, Berbatis CG, Greatwood E. Standards of antimicrobial prescribing for prophylaxis in selected surgical operations: a study conducted in a teaching hospital. Med J Aust 1981; 2: 238-241. 

 

27. Berbatis CG. Communication in Australian pharmacy: a study of society periodicals. Aust J Pharm 1981; 62: 616-618. 

 

28. Berbatis CG, Greenhill GT. Telephone follow-up and patient care: potential for pharmacists. Aust J Pharm 1982; 63: 28-29. 

 

29. Berbatis CG, Maher M, Plumridge RJ, Stoelwinder JU, Zubrick SR. The impact of a drug bulletin on prescribing oral analgesics in a teaching hospital. Am J Hosp Pharm 1982; 38: 98-100. 

 

30. Berbatis CG, Sunderland VB. Professional activities of Australian community pharmacists. Part 1: Evaluation of prescription-related activities. Aust J Pharm 1982; 63: 283-289. 

 

31. Berbatis CG, Kailis SG. Foundations of community pharmacy practice. Part 1: Prescription drug usage in Australia. Aust J Pharm 1982; 63: 139-141. 

 

32. Plumridge RJ, Stoelwinder JU, Berbatis CG. Improving patient care and pharmacy management: the effect of hospital formularies. Drug Intell Clin Pharm 1984; 18: 652-656. 

 

33. Berbatis CG, Sutherland VB. Professional activities of Australian community pharmacists. Part 2: The current status of primary health care and health promotion. Aust J Pharm 1985; 66: 169-174, 251-254, 337-340, 349. 

 

34. Berbatis CG. Strategies for improving drug use in hospitals. Aust Health Review 1984; 7(4); 253-9. 18 peer-reviewed 

 

35. McNeil V, Berbatis CG. Advances in the treatment of alcohol withdrawal syndrome. Aust J Hosp Pharm 1984; 14: 85-6. 

 

36. Berbatis CG, Sunderland VB. Indexing the PBS professional dispensing fee against performance. Aust J Pharm 1985; 66: 298-301, 304. 

 

37. Birkett D, Berbatis CG, et al. Drug interactions that matter. Current Therapeutics 1985; 26(7): insert. 

 

38. Paterson J, Blackbourn J, Berbatis CG, Jackson S. A study of hyperlipidaemic inpatients: implications for pharmacists. Aust J Hosp Pharm 1985; 15(3); 147- 50. 

 

39. Berbatis CG. Community pharmacists' contribution to health care in Australia: a quantitative approach. Australian Pharmacist 1986; 5: 3-4. 

 

40. Berbatis CG. Coronary heart disease, diet and drugs: new approaches for hospital dietitians. J Food Nutrition 1985; 42: 175-178. 

 

41. Berbatis CG. Clinical trials in an Australian teaching hospital: problems and procedures. Aust Health Rev 1986; 9: 116-123. 

 

42. Hurley SF, McNeil JJ, Berbatis CG. Sources of Australian pharmacoepidemiology data. Comm Health Studies 1988; 12: 82-96 

 

43. Plumridge RJ, Berbatis CG. Drug bulletins: effectiveness in modifying prescribing and methods of improving impact. Drug Intell Clin Pharm (Annals of Pharmacohemotherapy) 1989; 23: 330-334 

 

44. Li SC, Ionnides-Demos LL, Spicer WJ, Berbatis CG, Spelman DW, Tong N, McLean AJ. Prospective audit of aminoglycoside usage in general hospital with assessments of clinical processes and adverse clinical outcomes. Med J Aust 1989; 15: 224-232. 

 

45. Berbatis CG, Sullivan B. Smoking, drugs and smoking cessation. Part 2: relationship between tobacco smoking and disease - application by pharmacists. Australian Pharmacist 1989; 8: 139-144. 

 

46. Berbatis CG, Sullivan B. Smoking, drugs and smoking cessation. Part 3: smoking cessation methods - an evaluation and proposed initiatives for Australian pharmacists. Australian Pharmacist 1989; 8: 172-179. 

 

47. Berbatis CG. Public health and hospital pharmacy: the case of smoking. Aust J Hosp Pharm 1990; 20: 209-10. 

 

48. Lockwood A, Berbatis CG. Psychotropic drugs in Australia: consumption patterns. Med J Aust 1990; 153: 604-611. 

 

49. Lockwood A, Berbatis CG. Benzodiazepine drug use in Australia: associated mortality and morbidity. Drug Alcohol Rev 1990; 3: 277-287. 

 

50. Berbatis CG. The Morgan Gallup Polls: an outcome measure of community pharmacy? Australian Pharmacist 1990; 9: 103-104. 

 

51. Berbatis CG. Nicorettes 2 mg: the first effective smoking cessation agent with P status. Pharm J 1991; 247: 212-214. 

 

52. Berbatis CG, Sunderland VB. Lifestyle risk factor management: a basis for interventions on tobacco smoking by hospital pharmacists. Aust J Hosp Pharm 1992; 22: 68-72. 

 

53. Berbatis CG. Pharmacoeconomics: advent of a new pharmacy science. Aust J Pharm 1992; 73: 78. 

 

54. Berbatis CG. The National Health Strategy and pharmacy in public hospitals. Aust J Pharm 1992; 73: 486-487. 

 

55. *Berbatis C, Fox R, Mathews I, Book review: Drug Policy: fact, fiction and the future. Aust J Hosp Pharm 1993; 23: 136-7. 

 

56. Berbatis C, Goodman M, Jessop J. Laboratory tests and community pharmacy practice in Australia: time for national action. Australian Pharmacist 1994; 13(2): 33-36 

 

57. Berbatis CG, Chemoprevention. Aust Pharmacist 1994; 13: 501. 

 

58. Berbatis CG, Chemoprevention of cancer: an update. Aust Pharmacist 1994;13: 501-4. 

 

59. Berbatis CG, Chemoprevention and cardiovascular disorders. Part 1: Antioxidant agents. Aust Pharmacist 1994; 13(11): 740-2, 750. 

 

60. Berbatis C G, Chemoprevention of cardiovascular disorders. Part 2: Agents in primary prevention. Aust Pharmacist 1995; 14(3): 79-84. 

 

61. Berbatis CG, Chemoprevention of cardiovascular disorders. Part 3: Agents in secondary prevention. Aust Pharmacist 1995; 14(4): 163- 166. 14peer-reviewed 

 

62. Berbatis CG, Aspirin in the chemoprevention of cardiovascular disorders. Aust Pharmacist 1995; 14(10): 610-613. 

 

63 Berbatis CG, Sunderland VB. A point of reference for health promotion. Australian Pharmacist 1996; 15: 83-85, 108. 

 

64. Berbatis CG, Hopkins P, Ladhams B, Tran U, Haigh D, Phillips M. A comparison of methadone and non-methadone treatment pharmacies in Western Australia: activities, perceptions and adverse outcomes. Proceedings of the Second National Methadone Conference 1996. North Melbourne: Secretariat 1996 National Methadone Conference; 1997: 57-63. 

 

65. Berbatis CG. Methadone programs, harm reduction, chronic diseases and hospital pharmacists. Aust J Hosp Pharm 1998; 28: 41-4. 

 

66. Berbatis CG, Sunderland VB, Bulsara M, Lintzeris N. Trends in licit opioid use in Australia ,1984-1988: comparative analysis of international and jurisdictional data. Med J Aust 2000;173: 524-527. 

 

67. Berbatis CG. National survey of Australia’s community pharmacies in 2002: rationale and methodology. J Pharm Pract Res 2002; 32: 143-146 

 

68. Berbatis C. National community pharmacy database project - Australia 2002. Pharmacy Review 2002; 26 (3) : 57-58. 

 

69. Berbatis C. Clinical testing in pharmacies. Pharmacy Review 2002; 26 (3) : 59-60. 

 

70. Berbatis. The war for vaccines in community pharmacies. Pharmacy Review 2002; 26(4 ): 39-40 

 

71. Berbatis CG, Sunderland VB, Bulsara M. Licit psychostimulant consumption in Australia, 1984-2000: international and jurisdictional comparison. Med J Aust 2002; 177: 539-543. 

 

72. Berbatis C. Practice postcard from the US. Part 1: comparisons and contrasts. Aust J Pharm 2003; 84: 628-629. 

 

73. Berbatis C. Practice postcard from the US. Part 1: prediction of trends to 2020. Aust J Pharm 2003; 84: 534-536. 

 

74. Berbatis C. Post-McAnuff consequences for pharmacy in Australia. Pharmacy Review 2004; 28(2 ): 23-26. 

 

75. Berbatis. Community pharmacies’ harm reduction in Australia. Part 1. Participation and provision. Pharmacy Review 2004; 28(2 ): 37-40. 

 

76. Berbatis C. Act now to reduce pharmacy shopping. Aust J Pharm 2004; 85: 678. 

 

77. Berbatis C. Weight management and the challenges to Australian pharmacy. Aust Pharmacist 2005; 24: 196-201, 242. 

 

78. Berbatis CG, Sunderland VB, Joyce A, Bulsara M, Mills C. Enhanced pharmacy services, barriers and facilitators in Australia’s community pharmacies: Australia’s National Pharmacy Database Project. International J Pharmacy Practice 2007; 15:185-191 

 

79. Berbatis CG, Sunderland VB, Joyce A, Bulsara M, Mills C. Characteristics of Australia’s community pharmacies: National Pharmacy Database Project. International J Pharmacy Practice 2007; 15: 265-271. 

 

80. Joyce A, Berbatis CG, Sunderland VB, Dahliwal SS. Analysis of primary prevention in Australia’s community pharmacies. Aust N Z J Public Health 2007; 31:516-519. 

 

81. Berbatis CG, Sunderland VB. Community pharmacy contribution to health in Australia: 1. Population studies of non-dispensing primary care. Aust Pharmacist 2008 (accepted). 

 

82. Berbatis CG, Sunderland VB, Dhaliwal. S. Linked electronic medication systems in community pharmacies for preventing pseudoephedrine diversion: analysis of results in Australia. Drug and Alcohol Review 2008 (accepted). 

​